Expert Interview
A third opinion: Does Squalamine stand a good chance of success in the current Phase 3 Wet AMD trial?
Ticker(s): OHRP, REGN, NVS, OphthotechAn Ophthalmologist with extensive experience treating Wet AMD patients and ideally developing therapies for the disease. Knowledge of the long history of squalamine is essential.
Please describe your practice briefly. How do you split your time seeing patients, conducting research and teaching/other responsibilities?
In what capacity are you familiar with the OHR-102 (squalamine) data for Wet- AMD?
There has been controversy over the years whether an eye drop is able to deliver drug to the “back of the eye.” Can you give us your view on whether OHR-102 is delivering drug to the back of the eye, and if yes, how it does that/what kind of data is available as evidence?
What is your opinion on Squalamine and it's potential for success in the current Phase 3 trials?
Based on the Phase 2 results and subsequent analysis, if asked, would you recommend to a large pharmaceutical company that it is likely worth the risk to partner with Ohr Pharmaceutical for the development of Squalamine for Wet AMD at this time ($100MM up front + milestones & royalties?
There has been controversy over the years whether an eye drop is able to deliver drug to the “back of the eye.” Can you give us your view on whether OHR-102 is delivering drug to the back of the eye, and if yes, how it does that/what kind of data is available as evidence?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
